Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML

Katarina Micin, Tiffany Nong, Ellen Madarang, Kiana Robles, Maurizio Affer, Brittney Otero, Azad Gucwa, Felipe Novoa, Sion Williams, Ana Ayupe, Yi Zhou, Justin M. Watts, Justin Taylor

Blood (2024) 144 (Supplement 1): 4333.

https://doi.org/10.1182/blood-2024-207400

Published: 2024

Journal Articles

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Mikkael A. Sekeres, Sangeetha Venugopal, Namrata S. Chandhok, Justin M. Watts, Terrence Bradley, Justin Taylor, David Sallman, Zhuoer Xie, Eric Padron, Shelby Sullivan, Emily Zyborowicz, Jeffrey Carter, Cherilyn Heggen, Lindsay Gurska, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 3679.

https://doi.org/10.1182/blood-2024-203444

Published: 2024

Journal Articles

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, Hetty E. Carraway, Richard M Stone, Yazan F Madanat, Rami S. Komrokji, Sangeetha Venugopal, Namrata S. Chandhok, Terrence Bradley, Justin Taylor, Anastasia Santiago, Alessia Zoso, Justin M. Watts, Amy E. DeZern

Blood (2024) 144 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2024-203965

Published: 2024

Journal Articles

Genomic Proximity Mapping (GPM): Evaluation of a Next Generation Cytogenomic Assay for Improved Risk Stratification in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6157.

https://doi.org/10.1182/blood-2024-211570

Published: 2024

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2024) 144 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2024-193966

Published: 2024

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Blood (2024) 144 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2024-210872

Published: 2024

Journal Articles

Altered RNA Export in SF3B1 Mutants Increases Sensitivity to Nuclear Export Inhibition

Sana Chaudhry, Felipe Beckedorff, Tulasigeri M Totiger, Maurizio Affer, Nidhi Hariramani, Skye Montoya, Alyssa Cornista, Daniel Bilbao, Evan R. Roberts, Jumana Afaghani, Jose Antonio Rodríguez, Eric Wang, Justin Taylor

Blood (2023) 142 (Supplement 1): 44.

https://doi.org/10.1182/blood-2023-182877

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Distinct SF3B1 Allele HEAT Repeat Location Is Associated with Co-Occurring Mutation Patterns in MDS

David Bared Dukenik, Deborah Soong, Frank Scarpa, Julia Anderson, Hua Li, Viji Udayakuma, Justin M. Watts, Yazan F. Madanat, Mikkael A. Sekeres, Namrata Sonia Chandhok, Justin Taylor

Blood (2023) 142 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2023-181191

Published: 2023

Journal Articles

E7820, an Anti-Cancer Sulfonamide, in Combination with Venetoclax in Patients with Splicing Factor Mutant Myeloid Malignancies: A Phase II Clinical Trial

Jan Philipp Bewersdorf, Namrata Sonia Chandhok, Justin M. Watts, Andriy Derkach, Omar Abdel-Wahab, Eytan M. Stein, Justin Taylor

Blood (2023) 142 (Supplement 1): 1547.

https://doi.org/10.1182/blood-2023-182369

Published: 2023

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2023) 142 (Supplement 1): 6740.

https://doi.org/10.1182/blood-2023-180939

Published: 2023

Journal Articles

The LSD1 Inhibitor Ory-1001 (ladademstat) in Combination with Menin Inhibitor SNDX-5613 (revumenib) Has Synergistic in Vitro Activity in KMT2A -Rearranged AML Models

Mina M. Tayari, Tulasigeri M Totiger, Ramin Shiekhattar, Justin Taylor, Justin M. Watts

Blood (2023) 142 (Supplement 1): 5691.

https://doi.org/10.1182/blood-2023-190309

Published: 2023

Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Blood (2023) 141 (19): 2359–2371.

https://doi.org/10.1182/blood.2022018244

Published: 2023

Includes: Supplemental data

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M. Stone, Alan Saven, Jessica K. Altman, Michael R. Grever, Kanti R. Rai, Madhulika Shukla, Shreya Vemuri, Skye Montoya, Justin Taylor, Omar Abdel-Wahab, Martin S. Tallman, Jae H. Park

Blood (2022) 140 (25): 2663–2671.

https://doi.org/10.1182/blood.2022016183

Published: 2022

Journal Articles

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood (2022) 140 (Supplement 1): 2887–2890.

https://doi.org/10.1182/blood-2022-162367

Published: 2022

Journal Articles

Splicing Modulators Impair DNA Damage Response and Induce Killing of Cohesin-Mutant MDS/AML

Emily C Wheeler, Benjamin Martin, William Doyle, Rebecca Gorelov, Melanie Donahue, Johann-Christoph Jann, Omar Abdel-Wahab, Justin Taylor, Michael Seiler, Silvia Buonamici, Roger Belizaire, Karen Adelman, Zuzana Tothova

Blood (2022) 140 (Supplement 1): 6888–6889.

https://doi.org/10.1182/blood-2022-170996

Published: 2022

Journal Articles

Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy

Blood (2022) 140 (Supplement 1): 3306–3308.

https://doi.org/10.1182/blood-2022-170771

Published: 2022

Journal Articles

Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders

Blood (2022) 140 (Supplement 1): 1811–1813.

https://doi.org/10.1182/blood-2022-163268

Published: 2022

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Genomic Proximity Mapping (GPM): Evaluation of a Next Generation Cytogenomic Assay for Improved Risk Stratification in Acute Myeloid Leukemia

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Altered RNA Export in SF3B1 Mutants Increases Sensitivity to Nuclear Export Inhibition

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Distinct SF3B1 Allele HEAT Repeat Location Is Associated with Co-Occurring Mutation Patterns in MDS

E7820, an Anti-Cancer Sulfonamide, in Combination with Venetoclax in Patients with Splicing Factor Mutant Myeloid Malignancies: A Phase II Clinical Trial

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

The LSD1 Inhibitor Ory-1001 (ladademstat) in Combination with Menin Inhibitor SNDX-5613 (revumenib) Has Synergistic in Vitro Activity in KMT2A -Rearranged AML Models

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Splicing Modulators Impair DNA Damage Response and Induce Killing of Cohesin-Mutant MDS/AML

Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy

Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only